The life science group Sartorius, through its French listed subgroup Sartorius Stedim Biotech, has successfully closed the acquisition of the French company Polyplus. The transaction was completed today, after receiving the required regulatory approvals.
Polyplus is a leading provider of innovative technologies for cell and gene therapies. Transfection reagents developed and produced by Polyplus are key components in the manufacture of viral vectors. The company has been expanding its focus beyond this field through acquisitions in adjacent technologies like plasmid design, and protein and plasmid manufacturing, broadening its portfolio for gene therapies as well as gene-modified cell therapies.